Oviva Therapeutics, A Cambrian Biopharma *Pipeco, Announces Seed Financing And Exclusive License With Massachusetts General Hospital To Develop Therapeutics To Extend Healthspan In Women
Oviva Therapeutics, A Cambrian Biopharma *Pipeco, Announces Seed Financing And Exclusive License With Massachusetts General Hospital To Develop Therapeutics To Extend Healthspan In Women
05/19/22, 9:01 AM
Round Type
seed
Oviva Therapeutics, Inc. (Oviva), the women's health biotech company and a Cambrian Biopharma *PipeCo, today announced an in-licensing agreement with Massachusetts General Hospital (MGH) of a family of patents, as well as $11.5 million in Seed funding, to develop first-in-class therapeutics to improve healthspan – the period of life spent in good health - in women. Oviva Therapeutics addresses the vast unmet need in women's health by expanding funding, research, and clinical development of treatments addressing female physiology, beginning with a focus on ovarian aging.
Company Info
Additional Info
Oviva Therapeutics, Inc. is leading a movement to improve women's experience of aging through biomedical research, development and advocacy. Oviva addresses the vast unmet need in women's health by expanding funding, research, and clinical development, and is currently developing first-in-class therapeutics to improve ovarian function and consequently extend female healthspan.
Company news
Wed, 30 Jan 2019 08:00:00 GMT
Oral versus Intravenous Antibiotics for Bone and Joint Infection - nejm.org
Fri, 19 Aug 2022 07:00:00 GMT
Delaying menopause could slow the aging process - Labiotech.eu
Wed, 20 Dec 2023 08:00:00 GMT
The Biggest Breakthrough in Longevity May Start With Menopause - Bloomberg
Tue, 31 Aug 2021 07:00:00 GMT
Oviva grabs $80M for app-delivered healthy eating programs - TechCrunch
Recognized as a G2 High Performer
Unlock Real-Time Insights to Close More Deals
Stay ahead with lightning-fast updates on funding rounds, acquisitions, executive hires, and more—all powered by AI-driven tools.